Objectives:To investigate the distribution and change of the burden of cardiovascular diseases attributable to tobacco consumption in China and the world from 1990 to 2021.Methods:Based on Global Burden of Disease(GBD)2021 database,age standardized mortality and age standardized disability-adjusted life year(DALY)rates and estimated annual percentage change(EAPC)from cardiovascular disease(including ischemic heart disease,stroke,atrial fibrillation and flutter,aortic aneurysm,peripheral artery disease)attributable to tobacco consumption were analyzed.The association of the human development index(HDI)and social demographic index(SDI)with age-standardized mortality was also analyzed.Results:Compared to 1990,the global burden of cardiovascular diseases attributable to smoking declined in 2021,age-standardized mortality decreased from 57.2/100 000 to 26.3/100 000(EAPC=-1.81%,95% CI:-2.00% to-1.63% ).The global burden of cardiovascular diseases attributable to second-hand smoke also decreased,age-standardized mortality decreased from 11.4/100 000 to 8.3/100 000(EAPC=-1.72%,95% CI:-1.91% to-1.53% ).In China,the burden of cardiovascular diseases attributable to smoking also decreased,age-standardized mortality decreased from 52.2/100 000 to 39.6/100 000(EAPC=-1.23%,95% CI:-1.44%-1.02% );the burden of cardiovascular diseases attributable to second-hand smoke decreased,age-standardized mortality decreased from 15.3/100 000 to 14.7/100 000(EAPC=-1.26%,95% CI:-1.63% to-0.90% ).Notably,the decrease in cardiovascular diseases burden attributable to second-hand smoke among Chinese women was more significant than the global level,the age-standardized mortality rate of Chinese women decreased from 17.9/100 000 to 14.5/100 000(EAPC=-2.24%,95% CI=-2.78%～-1.86% ).Among the five types of cardiovascular diseases attributable to tobacco consumption globally and in China,the age-standardized mortality and age-standardized DALY rates of aortic aneurysm,ischemic heart disease and peripheral artery disease were higher.Globally,ischaemic heart disease is the leading cause of death,accounting for 60.2% in 1990 and 61.7% in 2021,while stroke is the leading cause of death in China,accounting for 68.1% and 51.4% in 1990 and 2021,respectively.In addition,HDI and SDI are the two main factors affecting the disease burden.In regions and countries with SDI>7.2,age standardized mortality is below our forecast line.In the later part of the forecast,China's age standardized mortality showed a downward trend,possibly due to changes in tobacco control measures.Conclusions:Over the past 30 years,the burden of cardiovascular diseases attributed to tobacco consumption has decreased globally and in China.The decline in disease burden has been most pronounced among women.However,in countries and regions with an SDI below 7.2,the burden of disease remains significant high.Therefore,it is necessary to take tobacco control measures in key regions(China,East Asia,Central Europe,Central Asia and Southeast Asia)to actively reduce smoking rates and exposure to secondhand smoke in public places,so as to reduce the burden of cardiovascular diseases.

Plant virus nanoparticles(PVNPs)have inherent immune stimulation ability,which has been widely studied as an immune adjuvant to stimulate the anti-tumor immune response.PVNPs not only have the potential to be used as vaccine adjuvants for cancer immunotherapy,but also as delivery systems for single immunotherapy or combination therapies.Among them,PVNPs have achieved great success in preclinical research of cancer immunotherapy.The new immunotherapy strategy is to use PVNPs as in situ vaccination(ISV),which can effectively inhibit tumor growth and produce a widening systemic anti-tumor immune response after in-tratumoral administration;in addition,PVNPs in combination with other tumor treatment modalities may also improve the local and systemic anti-tumor immune response.In this review,the application and prospects of plant virus nanoparticles in cancer immunotherapy are reviewed,in order to provide new ideas for cancer immunotherapy.

The percutaneous osseointegrated prosthesis anchors the prosthetic limb directly to the residual skeleton, obviating the requirement for soft tissues dependent load transmission, suspension or prosthetic control. This permitting external loads to be conveyed directly from the prosthesis to the skeletal system. Thus, osseointegrated prostheses can circumvent many of the limitations associated with conventional socket prostheses, such as skin breakdown and poor socket fit—problems that are particularly prevalent among patients with major limb amputations. To date, over ten percutaneous osseointegration implant systems have progressed to various stages of clinical trials. Among those, three systems—OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees), ILP (Integral Leg Prosthesis), and OPL (Osseointegrated Prosthetic Limb)—have advanced to standardized clinical implementation and have generated substantial longitudinal patient data for scientific evaluation. Candidates for osseointegration surgery are typically required to meet several criteria: documented intolerance or complications attributable to traditional socket prostheses; skeletally maturity with adequate bone volume in the residual limb; capacity for adhere to postoperative rehabilitation protocols strictly; and overall satisfactory systemic health. Nevertheless, universally accepted clinical indications and contraindications for osseointegration remain lacking. The procedure is generally performed as a single stage operation; however, in cases with compromised preoperative systemic health or suboptimal local soft tissue conditions, a two-stage strategy may be adopted. The inter-stage interval typically ranges from 6 weeks to 6 months, providing sufficient time for soft tissue healing and robust osseointegration establishment. Evidence indicates that following successful osseointegration, patients exhibit improvements in prosthetic wearing frequency, mobility, systemic health status, and pain scores. Although complications, including infection, periprosthetic fracture, and mechanical failure, can still be recognized, the overall complication rate remains comparatively low. Percutaneous osseointegrated prosthetic systems are in an early phase of clinical adoption and mandate multidisciplinary collaboration throughout the treatment continuum. Osseointegrated prostheses demonstrate significant promise and may ultimately evolve into a standard of care intervention, enabling amputees to achieve superior functional outcomes.

Plant virus nanoparticles(PVNPs)have inherent immune stimulation ability,which has been widely studied as an immune adjuvant to stimulate the anti-tumor immune response.PVNPs not only have the potential to be used as vaccine adjuvants for cancer immunotherapy,but also as delivery systems for single immunotherapy or combination therapies.Among them,PVNPs have achieved great success in preclinical research of cancer immunotherapy.The new immunotherapy strategy is to use PVNPs as in situ vaccination(ISV),which can effectively inhibit tumor growth and produce a widening systemic anti-tumor immune response after in-tratumoral administration;in addition,PVNPs in combination with other tumor treatment modalities may also improve the local and systemic anti-tumor immune response.In this review,the application and prospects of plant virus nanoparticles in cancer immunotherapy are reviewed,in order to provide new ideas for cancer immunotherapy.

The percutaneous osseointegrated prosthesis anchors the prosthetic limb directly to the residual skeleton, obviating the requirement for soft tissues dependent load transmission, suspension or prosthetic control. This permitting external loads to be conveyed directly from the prosthesis to the skeletal system. Thus, osseointegrated prostheses can circumvent many of the limitations associated with conventional socket prostheses, such as skin breakdown and poor socket fit—problems that are particularly prevalent among patients with major limb amputations. To date, over ten percutaneous osseointegration implant systems have progressed to various stages of clinical trials. Among those, three systems—OPRA (Osseointegrated Prostheses for the Rehabilitation of Amputees), ILP (Integral Leg Prosthesis), and OPL (Osseointegrated Prosthetic Limb)—have advanced to standardized clinical implementation and have generated substantial longitudinal patient data for scientific evaluation. Candidates for osseointegration surgery are typically required to meet several criteria: documented intolerance or complications attributable to traditional socket prostheses; skeletally maturity with adequate bone volume in the residual limb; capacity for adhere to postoperative rehabilitation protocols strictly; and overall satisfactory systemic health. Nevertheless, universally accepted clinical indications and contraindications for osseointegration remain lacking. The procedure is generally performed as a single stage operation; however, in cases with compromised preoperative systemic health or suboptimal local soft tissue conditions, a two-stage strategy may be adopted. The inter-stage interval typically ranges from 6 weeks to 6 months, providing sufficient time for soft tissue healing and robust osseointegration establishment. Evidence indicates that following successful osseointegration, patients exhibit improvements in prosthetic wearing frequency, mobility, systemic health status, and pain scores. Although complications, including infection, periprosthetic fracture, and mechanical failure, can still be recognized, the overall complication rate remains comparatively low. Percutaneous osseointegrated prosthetic systems are in an early phase of clinical adoption and mandate multidisciplinary collaboration throughout the treatment continuum. Osseointegrated prostheses demonstrate significant promise and may ultimately evolve into a standard of care intervention, enabling amputees to achieve superior functional outcomes.

Objectives:To investigate the distribution and change of the burden of cardiovascular diseases attributable to tobacco consumption in China and the world from 1990 to 2021.Methods:Based on Global Burden of Disease(GBD)2021 database,age standardized mortality and age standardized disability-adjusted life year(DALY)rates and estimated annual percentage change(EAPC)from cardiovascular disease(including ischemic heart disease,stroke,atrial fibrillation and flutter,aortic aneurysm,peripheral artery disease)attributable to tobacco consumption were analyzed.The association of the human development index(HDI)and social demographic index(SDI)with age-standardized mortality was also analyzed.Results:Compared to 1990,the global burden of cardiovascular diseases attributable to smoking declined in 2021,age-standardized mortality decreased from 57.2/100 000 to 26.3/100 000(EAPC=-1.81%,95% CI:-2.00% to-1.63% ).The global burden of cardiovascular diseases attributable to second-hand smoke also decreased,age-standardized mortality decreased from 11.4/100 000 to 8.3/100 000(EAPC=-1.72%,95% CI:-1.91% to-1.53% ).In China,the burden of cardiovascular diseases attributable to smoking also decreased,age-standardized mortality decreased from 52.2/100 000 to 39.6/100 000(EAPC=-1.23%,95% CI:-1.44%-1.02% );the burden of cardiovascular diseases attributable to second-hand smoke decreased,age-standardized mortality decreased from 15.3/100 000 to 14.7/100 000(EAPC=-1.26%,95% CI:-1.63% to-0.90% ).Notably,the decrease in cardiovascular diseases burden attributable to second-hand smoke among Chinese women was more significant than the global level,the age-standardized mortality rate of Chinese women decreased from 17.9/100 000 to 14.5/100 000(EAPC=-2.24%,95% CI=-2.78%～-1.86% ).Among the five types of cardiovascular diseases attributable to tobacco consumption globally and in China,the age-standardized mortality and age-standardized DALY rates of aortic aneurysm,ischemic heart disease and peripheral artery disease were higher.Globally,ischaemic heart disease is the leading cause of death,accounting for 60.2% in 1990 and 61.7% in 2021,while stroke is the leading cause of death in China,accounting for 68.1% and 51.4% in 1990 and 2021,respectively.In addition,HDI and SDI are the two main factors affecting the disease burden.In regions and countries with SDI>7.2,age standardized mortality is below our forecast line.In the later part of the forecast,China's age standardized mortality showed a downward trend,possibly due to changes in tobacco control measures.Conclusions:Over the past 30 years,the burden of cardiovascular diseases attributed to tobacco consumption has decreased globally and in China.The decline in disease burden has been most pronounced among women.However,in countries and regions with an SDI below 7.2,the burden of disease remains significant high.Therefore,it is necessary to take tobacco control measures in key regions(China,East Asia,Central Europe,Central Asia and Southeast Asia)to actively reduce smoking rates and exposure to secondhand smoke in public places,so as to reduce the burden of cardiovascular diseases.

In order to promote the innovative application of Sanjiao theory and Yingwei theory， this paper tries to apply the ''Sanjiao-Yingwei'' Qi transformation theory to the treatment of tumor diseases， integrating it with T cell exhaustion mechanism to elaborate on its scientific connotation and using network pharmacology and bioinformatics to elucidate the correlation between the anti-tumor mechanism of ''Sanjiao-Yingwei'' Qi transformation and T cell exhaustion. The ''Sanjiao-Yingwei'' Qi transformation function is closely related to the immunometabolic ability of the human body， and the ''Sanjiao-Yingwei'' Qi transformation system constitutes the immunometabolic exchange system within and outside the cellular environment. Cancer toxicity is generated by the fuzzy Sanjiao Qi， and the long-term fuzzy Sanjiao Qi is the primary factor leading to T cell exhaustion， which is related to the long-term activation of T cell receptors by the high tumor antigen load in the tumor microenvironment. Qi transformation malfunction of the Sanjiao produces phlegm and collects stasis， which contributes to T cell exhaustion and is correlated with nutrient deprivation， lipid accumulation， and high lactate levels in the immunosuppressed tumor microenvironment， as well as with the release of transforming growth factor-β and upregulated expression of programmed death receptor-1 by tumor-associated fibroblasts and platelets in the tumor microenvironment. Ying and Wei damage due to Sanjiao Qi transformation malfunction is similar to the abnormal manifestations such as progressive loss of exhausted T cell effector function and disturbance of cellular energy metabolism. Guizhi decoction， Shengming decoction， and Wendan decoction can correct T cell exhaustion and exert anti-tumor effects through multi-target and multi-pathways by regulating ''Sanjiao-Yingwei'' Qi transformation， and hypoxia inducible factor-1α （HIF-1α） may be one of the main pathways to correct T cell exhaustion. It was found that HIF-1α may be one of the important prognostic indicators in common tumors by bioinformatics. The use of the ''Sanjiao-Yingwei'' Qi transformation method may play an important part in improving the prognosis of tumor patients in clinical practice.

Objective:To study the postoperative complications and its risk factors in patients undergoing breast reconstruction with abdominal flaps.Methods:The clinical data of patients undergoing breast reconstruction with abdominal flaps at Department of Breast Oncoplastic Surgery, Tianjin Medical University Cancer Institute and Hospital from Jan 2011 to Apr 2022 were reviewed.Results:Postoperative complications occurred in 95 of 484 patients (19.6%), 15.5% had flap complications, 5.2% had donor-site complications, and fat necrosis was the most common complication (11.9%). The rate of fat liquefaction decreased significantly through technical improvement (1.7% vs. 7.0%); By univariate analysis, there were statistically significant differences among the groups by reconstructive type, neoadjuvant chemotherapy, BMI, smoking history ( χ2=21.088, P<0.001; χ2=4.385, P=0.036; χ2=14.784, P=0.018; χ2=19.015, P=0.048). Unplanned reoperation statistically related to the timing of reconstruction, and reconstructive type ( χ2=7.316, P=0.007; χ2=17.167, P<0.001). Revision surgery significantly related to the timing of reconstruction and timing of radiation ( χ2=40.785, P<0.001; χ2=18.602, P<0.001);By multivariate analysis, deep inferior epigastric perforator flap, smoking history were independent risk factors for flap necrosis ( OR=0.084, 95% CI:0.022-0.325, P<0.001; OR=41.623, 95% CI:3.241-534.569, P=0.004) . Conclusions:Complications after breast reconstruction with abdominal flaps are related to many factors. The surgical risks should be carefully evaluated and personalized plan should be formulated before surgery.

With the population aging, the prevalence rate of cardiovascular diseases in China continues to rise, among which, the mortality rate of aortic diseases is high, the treatment is difficult, and the risk is high. In recent years, the surgical treatment of aortic diseases in China has developed rapidly, and the overall scale has been increasing. This paper introduces the current status of treatment of aortic diseases in China, analyzes the medical quality of endovascular surgery and open surgery, including the number of operations, patient characteristics, mortality, readmission rate and other indicators, and compares the differences among different regions. In addition, advances in the treatment of aortic disease are discussed, including surgical methods, evaluation of effectiveness, and application of new technologies. Overall, China has made some progress in the treatment of aortic diseases, but it still faces the challenge of uneven distribution of medical resources and improvement of medical quality.

Objective:To compare the effect of self-radiopaque markers guiding physician-modified fenestration, chimney technique and hybrid Ⅳb technique on reconstruction of left subclavian artery (LSA) in endovascular treatment of aortic dissection (TEVAR).Methods:The clinical and follow-up data of 312 TEVAR patients treated with LSA blood supply reconstruction technology from Jan 2016 to Dec 2019 at Fuwai hospital were retrospectively analyzed.Results:There were 35 patients in the hybrid Ⅳb technique group, 93 in the chimney technique group, and 184 in the in vitro fenestration group. The follow-up period ranged from 12 to 24 months. No artificial blood vessel and stent occlusion occurred in all patients during follow-up, and the LSA blood flow was unobstructed. A total of 19 patients had endoleak by the last follow-up, and there was no statistical difference between the three groups. Eleven patients underwent reintervention surgery, all were from chimney technique group and in vitro fenestration group, with no statistical difference ( P>0.05). Severe complications occurred in 28 patients during hospitalization, and the incidence of complications was the highest in the hybrid Ⅳb technique group ( P<0.01). During follow-up, 4 patients died in the bypass group, 6 died in the external window group, and 8 died in the chimney group, with no significant difference ( P>0.05). Conclusions:The safety and efficacy of the left subclavian artery flow reconstruction by in vitro fenestration and chimney technique were similar. The occurrences of early complications were lower than that of the hybrid Ⅳb technique, but the reintervention rate of endoleak was higher.